Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA re-KAI COVID-19 revaccination immune response study in hematology patients
NL-OMON56570Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of mRNA COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Baseline loss of and residual SARS-CoV-2-specific cellular and humoral immunity, Antibody concentration 7 days after first revaccination and 2 more. Started May 2024; status: active, not recruiting.
02
Drugs
mRNA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON56570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56570.